Active	Status	Sponsor type	Region	Phase	Filter
10 Active 0 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Carpinteiro, Alexander
LINKER-MM1, NCT03761108 / 2018-003188-78: Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma Presentation of data from LINKER-MM1 trial in heavily pre-treated multiple myeloma at ASH 2022 Dec 2022 - Dec 2022: Presentation of data from LINKER-MM1 trial in heavily pre-treated multiple myeloma at ASH 2022 Completion of enrollment of trial for r/r multiple myeloma Dec 2022 - Dec 2022: Completion of enrollment of trial for r/r multiple myeloma Data from P1 portion of P1/2 trial for multiple myeloma at ASH 2021 Dec 2021 - Dec 2021: Data from P1 portion of P1/2 trial for multiple myeloma at ASH 2021 Data from P1 portion of P1/2 trial for multiple myeloma at ASH 2019 Dec 2019 - Dec 2019: Data from P1 portion of P1/2 trial for multiple myeloma at ASH 2019 From P1 portion of P1/2 trial for multiple myeloma at ASH 2019 Dec 2019 - Dec 2019: From P1 portion of P1/2 trial for multiple myeloma at ASH 2019 More	Recruiting	1/2	387	Europe, Japan, US, RoW	Linvoseltamab, REGN5458	Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc.	Multiple Myeloma	05/32	06/32
Röth, Alexander
NCT04661033 / 2020-003880-24: Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)	Terminated	2	8	Europe, US	Isatuximab SAR650984	Sanofi	Warm Autoimmune Hemolytic Anemia (wAIHA)	06/23	06/23
NCT05002777 / 2021-001671-16: Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA) Jul 2024 - Dec 2024 : Data from trial for warm autoimmune hemolytic anemia	Active, not recruiting	2	22	Europe, US, RoW	rilzabrutinib, PRN1008/SAR444671	Sanofi, Sanofi Aventis Recherche et Developpement	Warm Autoimmune Hemolytic Anemia (wAIHA)	05/24	05/25
Baum, Julia
No trials found